{"id":2406,"date":"2025-11-06T05:00:36","date_gmt":"2025-11-06T05:00:36","guid":{"rendered":"https:\/\/www.lunit.io\/en\/?post_type=media-hub&p=2406"},"modified":"2025-12-09T20:56:52","modified_gmt":"2025-12-10T01:56:52","slug":"volpara-now-operates-under-lunit-brand-advancing-a-unified-vision-for-ai-cancer-intelligence","status":"publish","type":"media-hub","link":"https:\/\/www.lunit.io\/en\/media-hub\/volpara-now-operates-under-lunit-brand-advancing-a-unified-vision-for-ai-cancer-intelligence\/","title":{"rendered":"Volpara Now Operates Under Lunit Brand, Advancing a Unified Vision for AI Cancer Intelligence"},"content":{"rendered":"

The rebranding marks the first phase of Lunit\u2019s unified global identity, connecting breast health, AI detection, and precision oncology under one name.<\/i><\/p>\n

 <\/p>\n

\"\"<\/p>\n

SEOUL, South Korea, November 6, 2025<\/strong> \u2014 Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and therapeutics, today announced that Volpara Health Technologies will now operate under the Lunit brand, introducing a unified global identity that merges their complementary strengths in breast health and AI innovation.<\/p>\n

This milestone builds on Lunit\u2019s 2024 acquisition of Volpara<\/a>, an important step that aligned both companies under one vision: to conquer cancer through AI.<\/p>\n

The integration builds a comprehensive ecosystem spanning risk prediction, early detection, imaging quality, and data-driven precision medicine, delivering greater value for clinicians, researchers, and patients worldwide. This positions Lunit among the few AI healthcare companies with a comprehensive cancer intelligence portfolio\u2014from breast health and screening to precision oncology\u2014serving over 10,000 healthcare providers across more than 65 countries.<\/p>\n

\u201cBy bringing Volpara under the Lunit brand, we\u2019re uniting our technologies, teams, and mission to deliver a connected ecosystem that transforms how cancer is detected and treated worldwide,\u201d said Brandon Suh, CEO of Lunit. \u201cThis marks the start of a new era of collaboration and impact across every stage of cancer care.\u201d<\/p>\n

To accelerate and enhance regional growth, Lunit is evolving its global operations under a unified structure. Lunit International (formerly Volpara Health Technologies), encompassing all former Volpara operations across the U.S., Latin America, and Oceania, will lead Lunit\u2019s business development and customer engagement efforts in these markets.<\/p>\n

In parallel, Lunit is transitioning part of its global sales organization into these regional hubs, allowing the Seoul headquarters to focus on AI research, innovation, and new product development\u2014further sharpening its global focus and specialization.<\/p>\n

As part of this milestone, Lunit has launched a newly designed website (www.lunit.io\/en<\/a>), reflecting its new digital identity and serving as a single digital gateway to its AI solutions, research, and corporate resources.<\/p>\n

\u201cOur mission remains the same,\u201d added Suh. \u201cWe aim to make AI the new standard for the entire cancer journey. We want every patient, regardless of geography or resources, to benefit from the same level of precision and insight, ensuring equitable access to life-saving diagnostics worldwide.\u201d<\/p>\n